All Updates

All Updates

icon
Filter
Funding
Artiva Biotherapeutics to raise USD 100 million in initial public offering
Cell & Gene Therapy
Jun 28, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Cell & Gene Therapy

Cell & Gene Therapy

Jun 28, 2024

Artiva Biotherapeutics to raise USD 100 million in initial public offering

Funding

  • Natural killer-based cell therapy developer Artiva Biotherapeutics has announced an IPO to raise to USD 100 million. This comes after an earlier IPO attempt in 2021 that was withdrawn in 2022. The company will start trading on the Nasdaq under the symbol "ARTV."

  • Although the specific use of the funds was undisclosed, the company is currently conducting Phase I/Ib trials for its lead candidate, AlloNK, for autoimmune diseases such as lupus nephritis and expects to reveal the initial data of the trials in 2025.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.